Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18F-FDG PET/CT

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma that typically presents with lymphadenopathy and extranodal involvement, most commonly affecting the spleen and gastrointestinal tract. Skeletal muscle infiltration is exceedingly rare, particularly in MCL. We report the case of a 64-year-old woman with MCL who initially achieved complete metabolic remission following R-CHOP chemotherapy and rituximab maintenance. However, restaging with 18F-FDG PET/CT revealed extensive skeletal muscle recurrence. This case underscores the critical role of 18F-FDG PET/CT in identifying atypical relapse patterns in MCL and highlights the need for vigilant, long-term surveillance following therapy.

Authors

Institutions

Publication Details

Journal
Clinical Nuclear Medicine
Published
2025-10-16
DOI
https://doi.org/10.1097/rlu.0000000000006163
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18F-FDG PET/CT

Srinivas Ananth Kumar, Prasanth Ganesan, Dhanapathi Halanaik, Harish Goyal et al.
Clinical Nuclear Medicine
Lymphoma Diagnosis and Treatment
article

Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18F-FDG PET/CT

Srinivas Ananth Kumar, Prasanth Ganesan, Dhanapathi Halanaik, Harish Goyal, Vishnu Balgi
article en

Abstract

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma that typically presents with lymphadenopathy and extranodal involvement, most commonly affecting the spleen and gastrointestinal tract. Skeletal muscle infiltration is exceedingly rare, particularly in MCL. We report the case of a 64-year-old woman with MCL who initially achieved complete metabolic remission following R-CHOP chemotherapy and rituximab maintenance. However, restaging with 18F-FDG PET/CT revealed extensive skeletal muscle recurrence. This case underscores the critical role of 18F-FDG PET/CT in identifying atypical relapse patterns in MCL and highlights the need for vigilant, long-term surveillance following therapy.

Clinical Nuclear Medicine
Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
Openalex Percentile: Top 50%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.